CISION PRNewswire

62536 posts
Heidrick & Struggles Announces 2024 Global and Regional Leader Appointments

Heidrick & Struggles Announces 2024 Global and Regional Leader Appointments

Promotions span six practice areas and three regions across business lines and…
Biesterfeld and Celanese: global expansion and enhanced joint portfolio as of 2024

Biesterfeld and Celanese: global expansion and enhanced joint portfolio as of 2024

HAMBURG, Germany, Jan. 3, 2024 /PRNewswire/ — International distributor Biesterfeld and leading…
Global Semiconductor Capacity Projected to Reach Record High 30 Million Wafers Per Month in 2024, SEMI Reports

Global Semiconductor Capacity Projected to Reach Record High 30 Million Wafers Per Month in 2024, SEMI Reports

MILPITAS, Calif., Jan. 2, 2024 /PRNewswire/ — Global semiconductor capacity is expected…
Innovative Smart Sports and Digital Health Tech From ITRI Debut at CES 2024

Innovative Smart Sports and Digital Health Tech From ITRI Debut at CES 2024

LAS VEGAS, Jan. 2, 2024 /PRNewswire/ — The Industrial Technology Research Institute (ITRI),…
Fairmonde Golf Welcomes LPGA Star Angel Yin as a Shareholder in a Groundbreaking Investment

Fairmonde Golf Welcomes LPGA Star Angel Yin as a Shareholder in a Groundbreaking Investment

Eco-friendly Golf Apparel Brand for Women Gains Momentum with Strategic Investment and…
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology

SUZHOU, China, Jan. 2, 2024 /PRNewswire/ — MediLink Therapeutics ("MediLink"), announced today that…
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

NATICK, Mass., Jan. 2, 2024 /PRNewswire/ — Allorion Therapeutics ("Allorion"), a US…